PMID- 21250412
OWN - NLM
STAT- MEDLINE
DCOM- 20110301
LR  - 20140730
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 149
IP  - 11
DP  - 2010 Nov
TI  - [Aspirin for primary prevention of cardiovascular diseases--lessons from recent 
      studies].
PG  - 712-4, 749, 748
AB  - Aspirin is recommended as a primary prevention treatment of cardiovascular 
      disease for the population at risk. The American Heart Association guidelines of 
      2002 recommended aspirin as primary prevention for patients with a cardiovascular 
      risk of over 10% per decade (according to the Framingham study). Over the last 
      few years, several double-blind controlled studies analyzed the affect of aspirin 
      for primary prevention in several population groups. For example, while the 
      effect of aspirin in men is mainly in lowering myocardial infarction risk, the 
      effect in women is mainly in lowering the risk of cerebrovascular accident. In 
      view of those studies, the U.S. Preventive Services Task Force (USPSTF) published 
      a gender-based set of guidelines for the use of aspirin as primary prevention. 
      Despite the studies and the USPSTF guidelines, controversy still persists 
      regarding aspirin as a primary prevention therapy. The available use of other 
      therapeutics as a measure for primary prevention and the different harm-benefit 
      ratio scaling for the aspirin effect, all contribute to the controversy. These 
      considerations have led some of the authors of articles in this edition to 
      recommend against administering aspirin as primary prevention. Studies in 
      diabetic patients have shown inferior results compared to the general population. 
      CONCLUSION: Despite tens of thousands of patients over the years, controversy 
      over aspirin as a primary prevention measure still prevails. Therefore, the 
      physician who decides on aspirin for primary prevention has to base his decision 
      on the unique characteristics of each specific patient.
FAU - Balmor, Gingy Ronen
AU  - Balmor GR
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
LA  - heb
PT  - Editorial
PT  - English Abstract
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/*prevention & control
MH  - Controlled Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Risk Assessment
EDAT- 2011/01/22 06:00
MHDA- 2011/03/02 06:00
CRDT- 2011/01/22 06:00
PHST- 2011/01/22 06:00 [entrez]
PHST- 2011/01/22 06:00 [pubmed]
PHST- 2011/03/02 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2010 Nov;149(11):712-4, 749, 748.